Solange Peters, Lizza Hendricks, and Martin Reck join Jonathan Blott to discuss The Lancet Respiratory Medicine Series on therapeutics in lung cancer, published to coincide with the Series launch at ERS 2026. The Series reviews developments in the treatment of non-small-cell lung cancer, from emerging approaches in early-stage disease to targeted therapies for advanced disease. The authors discuss the evidence supporting existing treatment strategies, areas of uncertainty in clinical practice, new and emerging biomarkers, and priorities for further research.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av,
eller tillsammans med, Poddtoppen.
